Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.

Shuhua ZhengYenong CaoJames RandallHaomin YuTarita O Thomas

Published in: Thoracic cancer (2023)

Current smokers have a five-fold increased risk of having POLE mutations than never-smokers. POLE/POLD1 mutation status and TMB > 18 can be a composite biomarker for selecting NSCLC patients with survival benefits to ICI treatment.

Keyphrases

smoking cessation
small cell lung cancer
combination therapy
replacement therapy
free survival
brain metastases